The University of Arkansas for Medical Sciences (UAMS) has received a five-year nearly $5.8 million grant from the National Institutes of Health (NIH) to continue research into the side effects of cancer therapies, including radiation and chemotherapy.
The $5,737,500 grant awarded by the NIH’s National Institute of General Medical Sciences funds Phase 3 of the UAMS Center for Studies of Host Response to Cancer Therapy, a Centers of Biomedical Research Excellence (COBRE) initiative, bringing the total federal investment in the center to more than $27 million since it was established in 2015.
Led by Marjan Boerma, PhD, associate director of basic science at the UAMS Winthrop P. Rockefeller Cancer Institute and the J. Thomas May Distinguished Endowed Chair in Oncology at UAMS, the center is the first COBRE research center of its kind in the United States dedicated exclusively to studying the side effects of cancer treatment.